Literature DB >> 12765341

Hypertension and angiotensin II hypersensitivity in aminopeptidase A-deficient mice.

Takashi Mitsui1, Seiji Nomura, Mayumi Okada, Yasumasa Ohno, Honami Kobayashi, Yutaka Nakashima, Yasutaka Murata, Mikihito Takeuchi, Naohiko Kuno, Tetsuo Nagasaka, Jiyang O-Wang, Max D Cooper, Shigehiko Mizutani.   

Abstract

Local concentrations of the vasopressor peptide, angiotensin II (AngII), depend upon the balance between synthesis and degradation. Previous studies of blood pressure (BP) regulation have focused primarily on the generation of AngII and its receptors, and less attention has been devoted to angiotensin degradation. Aminopeptidase A (APA, EC 3.4.11.7) is responsible for the N-terminal cleavage of AngII, a hydrolytic event that serves as a rate-limiting step in angiotensin degradation. To evaluate the physiological role of APA, we examined BP homeostasis in APA-deficient mice. We measured basal BP and BP with continuous infusion of AngII in APA mutant mice by tail-cuff method. We also evaluated the development and histology of AngII-targeted organs as well as urine excretion in these mice. Homozygous APA mutant mice were found to have elevated basal systolic BP when compared with heterozygous mutant and wild-type littermate mice. Infusion of AngII led to an enhanced systolic BP response in the APA-deficient mice. Despite the sustained elevation of BP in APA knockout mice, neither their renal and cardiac sizes nor their histological appearances were not different from control mice. Moreover, the volume, osmolality, and electrolyte content of the urine were normal in APA-deficient mice. APA deficiency increased baseline BP and enhanced the hypertensive response to increased levels of AngII. These findings indicate a physiological role for APA in lowering BP and offer novel insight into the mechanisms for developing hypertension.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12765341      PMCID: PMC1430374     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  30 in total

1.  A mammalian peptidase specific for the hydrolysis of N-terminal alpha-L-glutamyl and aspartyl residues.

Authors:  G G GLENNER; P J McMILLAN; J E FOLK
Journal:  Nature       Date:  1962-06-02       Impact factor: 49.962

2.  TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II.

Authors:  Jo El J Schultz; Sandra A Witt; Betty J Glascock; Michelle L Nieman; Peter J Reiser; Stacey L Nix; Thomas R Kimball; Thomas Doetschman
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

3.  Serum aminopeptidases, "angiotensinase," and hypertension. I. Degradation of angiotensin II by human serum.

Authors:  I Nagatsu; L Gillespie; J E Folk; G G Glenner
Journal:  Biochem Pharmacol       Date:  1965-05       Impact factor: 5.858

4.  Aminopeptidase A inhibitors as potential central antihypertensive agents.

Authors:  A Reaux; M C Fournie-Zaluski; C David; S Zini; B P Roques; P Corvol; C Llorens-Cortes
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

5.  Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension.

Authors:  S Ichihara; T Senbonmatsu; E Price; T Ichiki; F A Gaffney; T Inagami
Journal:  Circulation       Date:  2001-07-17       Impact factor: 29.690

6.  A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase.

Authors:  S R Tipnis; N M Hooper; R Hyde; E Karran; G Christie; A J Turner
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

Review 7.  The angiotensin-converting enzyme gene family: genomics and pharmacology.

Authors:  Anthony J Turner; Nigel M Hooper
Journal:  Trends Pharmacol Sci       Date:  2002-04       Impact factor: 14.819

8.  Angiotensin-converting enzyme 2 is an essential regulator of heart function.

Authors:  Michael A Crackower; Renu Sarao; Gavin Y Oudit; Chana Yagil; Ivona Kozieradzki; Sam E Scanga; Antonio J Oliveira-dos-Santos; Joan da Costa; Liyong Zhang; York Pei; James Scholey; Carlos M Ferrario; Armen S Manoukian; Mark C Chappell; Peter H Backx; Yoram Yagil; Josef M Penninger
Journal:  Nature       Date:  2002-06-20       Impact factor: 49.962

9.  Human kidney "enkephalinase", a neutral metalloendopeptidase that cleaves active peptides.

Authors:  J T Gafford; R A Skidgel; E G Erdös; L B Hersh
Journal:  Biochemistry       Date:  1983-06-21       Impact factor: 3.162

Review 10.  Proline specific endo- and exopeptidases.

Authors:  R Walter; W H Simmons; T Yoshimoto
Journal:  Mol Cell Biochem       Date:  1980-04-18       Impact factor: 3.396

View more
  20 in total

Review 1.  The importance of the intrarenal renin-angiotensin system.

Authors:  Juan Carlos Q Velez
Journal:  Nat Clin Pract Nephrol       Date:  2008-12-09

Review 2.  The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.

Authors:  Xiao C Li; Jianfeng Zhang; Jia L Zhuo
Journal:  Pharmacol Res       Date:  2017-06-12       Impact factor: 7.658

Review 3.  Atrial fibrillation in congestive heart failure.

Authors:  Steven A Lubitz; Emelia J Benjamin; Patrick T Ellinor
Journal:  Heart Fail Clin       Date:  2010-04       Impact factor: 3.179

4.  Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver.

Authors:  Sana Raza-Iqbal; Toshiya Tanaka; Motonobu Anai; Takeshi Inagaki; Yoshihiro Matsumura; Kaori Ikeda; Akashi Taguchi; Frank J Gonzalez; Juro Sakai; Tatsuhiko Kodama
Journal:  J Atheroscler Thromb       Date:  2015-06-04       Impact factor: 4.928

5.  Isolation of primitive endoderm, mesoderm, vascular endothelial and trophoblast progenitors from human pluripotent stem cells.

Authors:  Micha Drukker; Chad Tang; Reza Ardehali; Yuval Rinkevich; Jun Seita; Andrew S Lee; Adriane R Mosley; Irving L Weissman; Yoav Soen
Journal:  Nat Biotechnol       Date:  2012-05-27       Impact factor: 54.908

6.  Deficiency of the Angiotensinase Aminopeptidase A Increases Susceptibility to Glomerular Injury.

Authors:  Juan Carlos Q Velez; Ehtesham Arif; Jessalyn Rodgers; Megan P Hicks; John M Arthur; Deepak Nihalani; Evelyn T Bruner; Milos N Budisavljevic; Carl Atkinson; Wayne R Fitzgibbon; Michael G Janech
Journal:  J Am Soc Nephrol       Date:  2017-02-15       Impact factor: 10.121

Review 7.  Role of angiotensin III in hypertension.

Authors:  Annabelle Reaux-Le Goazigo; Xavier Iturrioz; Celine Fassot; Cedric Claperon; Bernard P Roques; Catherine Llorens-Cortes
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

8.  Functional genetic variation in aminopeptidase A (ENPEP): lack of clear association with focal and segmental glomerulosclerosis (FSGS).

Authors:  Stephen Tonna; Savita V Dandapani; Andrea Uscinski; Gerald B Appel; Johannes S Schlöndorff; Kang Zhang; Bradley M Denker; Martin R Pollak
Journal:  Gene       Date:  2007-12-03       Impact factor: 3.688

9.  Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension.

Authors:  Marie-Claude Fournie-Zaluski; Celine Fassot; Bruno Valentin; Dragan Djordjijevic; Annabelle Reaux-Le Goazigo; Pierre Corvol; Bernard P Roques; Catherine Llorens-Cortes
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-10       Impact factor: 11.205

10.  Identification and characterization of novel inhibitors of Mammalian aspartyl aminopeptidase.

Authors:  Yuanyuan Chen; Hong Tang; William Seibel; Ruben Papoian; Ki Oh; Xiaoyu Li; Jianye Zhang; Marcin Golczak; Krzysztof Palczewski; Philip D Kiser
Journal:  Mol Pharmacol       Date:  2014-06-09       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.